The pragmatic use of apomorphine at the end of life
Authors:
- 16 October 2009
- journal article
- other
- Published by SAGE Publications in Palliative Medicine
- Vol. 23 (8) , 777-779
Abstract
Parkinson’s Disease (PD) is an irreversible degenerative neurological disorder with no known cure. Apomorphine is a potent short-acting D1/D2 dopamine agonist administered sub-cutaneously that is used in the treatment of PD. Optimising PD medication is an important aspect of end of life care. There are no previously reported cases of apomorphine providing symptom relief in terminal care of PD patients. This case highlights its potential benefits for symptom control at the end of life.Keywords
This publication has 16 references indexed in Scilit:
- Measuring symptom load in Idiopathic Parkinson's diseaseParkinsonism & Related Disorders, 2007
- A Survey of Pain in Idiopathic Parkinson's DiseaseJournal of Pain and Symptom Management, 2006
- Individualized assessment of quality of life in idiopathic Parkinson's diseaseMovement Disorders, 2006
- Update on Apomorphine for the Rapid Treatment of Hypomobility (“Off”) Episodes in Parkinson's DiseasePharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2006
- A review of intermittent subcutaneous apomorphineinjections for the rescue management of motor fluctuations associated with advanced Parkinson's diseaseClinical Therapeutics, 2005
- A 10 year retrospective audit of long-term apomorphine use in Parkinson?s diseaseJournal of Neurology, 2004
- Subcutaneous ApomorphineDrugs & Aging, 2004
- Care of the dying patient: the last hours or days of lifeCommentary: a “good death” is possible in the NHSBMJ, 2003
- Pharmacological treatment of Parkinson’s diseasePostgraduate Medical Journal, 2000
- Practical approach to quality of life in Parkinson’s disease: the nurse’s roleJournal of Neurology, 1998